Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v1-EN
Language French English
Date Updated 2025-04-15 2025-03-13
Drug Identification Number 02501554 02501554
Brand name FENTANYL CITRATE INJECTION, USP FENTANYL CITRATE INJECTION, USP
Common or Proper name Fentanyl Citrate Injection, USP Fentanyl Citrate Injection, USP
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients FENTANYL FENTANYL
Strength(s) 50MCG 50MCG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAMUSCULAR EPIDURAL INTRAVENOUS INTRAMUSCULAR EPIDURAL
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 50mL 50mL
ATC code N01AH N01AH
ATC description ANESTHETICS, GENERAL ANESTHETICS, GENERAL
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2025-03-18 2025-03-18
Actual start date
Estimated end date 2025-04-15 2025-04-15
Actual end date 2025-04-11
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be encountering a supply interruption on our Fentanyl Citrate Injection, USP 50 mcg/mL PBP Vial 50 mL effective March 18, 2025, until April 15, 2025. Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be encountering a supply interruption on our Fentanyl Citrate Injection, USP 50 mcg/mL PBP Vial 50 mL effective March 18, 2025, until April 15, 2025.
Health Canada comments